Comments
Chennai-based Trivitron Healthcare, a medical technology company, has acquired 60 per cent stake in Turkish healthcare firm Bome Sanayi Urunleri Dis. Tic. Ltd, which has revenue of around ₹50 crore.
Trivitron has invested €5 million to pick up the stake, including share premium.
The remaining 40 per cent stake in the company that manufactures in-vitro diagnostic device will be held by promoters, says a press release quoting Trivitron’s Chairman and Managing Director GSK Velu.
The acquisition brings in growth capital and distribution network for Bome, which has been active in diagnostics since 1989 conducting new born screening tests on behalf of Turkish government.
It has screened over 1.8 million babies and does annually 10 million tests in Turkey.
The acquisition will help Trivitron have direct access to markets in Turkey, West Asia, Africa, South and South-East Asia.
It will also access Bome’s production facility, research labs and new born screening laboratory, the release said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.